Free tool
FAERS Monitor: Benicar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021286 or its brand name (Benicar, Olmesartan Medoxomil). Reports on generic versions are filed under their own applications.
Reports
36,093
Serious
23,598
65% of reports
Hospitalization
13,579
Death reported
1,635
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sprue-like enteropathy3,497
- diarrhoea2,512
- weight decreased2,231
- dizziness2,127
- gastrooesophageal reflux disease2,079
- nausea2,059
- acute kidney injury2,028
- drug ineffective1,997
- fatigue1,702
- headache1,428
- haemorrhoids1,369
- dyspnoea1,362
- hypotension1,330
- constipation1,315
- vomiting1,219
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 486 |
| 2005 | 567 |
| 2006 | 572 |
| 2007 | 777 |
| 2008 | 1,069 |
| 2009 | 1,285 |
| 2010 | 1,815 |
| 2011 | 1,741 |
| 2012 | 1,930 |
| 2013 | 1,205 |
| 2014 | 1,455 |
| 2015 | 2,878 |
| 2016 | 2,914 |
| 2017 | 3,142 |
| 2018 | 3,211 |
| 2019 | 2,113 |
| 2020 | 1,373 |
| 2021 | 1,203 |
| 2022 | 1,537 |
| 2023 | 1,436 |
| 2024 | 1,168 |
| 2025 | 1,210 |
| 2026 | 1,006 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,018,066 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sprue-like enteropathySignal | 3,497 | 1417.1 | 1333.9 | 1,441,206 |
| haemorrhoidsSignal | 1,369 | 43.9 | 41.6 | 53,383 |
| gastrooesophageal reflux diseaseSignal | 2,079 | 15.4 | 14.8 | 27,405 |
| acute kidney injurySignal | 2,028 | 7.8 | 7.5 | 11,969 |
| weight decreasedSignal | 2,231 | 4.7 | 4.5 | 6,501 |
| hypotensionSignal | 1,330 | 3.9 | 3.7 | 2,852 |
| constipationSignal | 1,315 | 3.5 | 3.3 | 2,391 |
| dizzinessSignal | 2,127 | 2.5 | 2.4 | 1,935 |
| diarrhoeaSignal | 2,512 | 2.3 | 2.2 | 1,839 |
| nausea | 2,059 | 1.5 | 1.5 | 376 |
| vomiting | 1,219 | 1.5 | 1.4 | 215 |
| dyspnoea | 1,362 | 1.4 | 1.3 | 161 |
| headache | 1,428 | 1.3 | 1.3 | 119 |
| fatigue | 1,702 | 1.3 | 1.2 | 104 |
| drug ineffective | 1,997 | 0.9 | 0.8 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.